OS Therapies (NYSEAMERICAN:OSTX) Upgraded to “Hold” at Zacks Research

OS Therapies (NYSEAMERICAN:OSTX) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

OSTX has been the subject of several other research reports. D. Boral Capital restated a “buy” rating and set a $20.00 price target on shares of OS Therapies in a research report on Thursday, April 30th. Lake Street Capital lowered their price target on shares of OS Therapies from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

OS Therapies Stock Performance

OS Therapies stock opened at $1.78 on Thursday. The company has a 50-day simple moving average of $1.61 and a 200-day simple moving average of $1.55. The firm has a market capitalization of $79.28 million, a P/E ratio of -1.65 and a beta of -0.95. OS Therapies has a one year low of $1.15 and a one year high of $2.57.

OS Therapies (NYSEAMERICAN:OSTX) last released its quarterly earnings results on Monday, May 18th. The company reported ($0.27) EPS for the quarter. As a group, sell-side analysts forecast that OS Therapies will post 0.16 earnings per share for the current year.

Hedge Funds Weigh In On OS Therapies

Several large investors have recently made changes to their positions in the business. State Street Corp lifted its stake in OS Therapies by 16.3% during the fourth quarter. State Street Corp now owns 58,500 shares of the company’s stock valued at $82,000 after buying an additional 8,200 shares in the last quarter. Jane Street Group LLC purchased a new stake in OS Therapies during the fourth quarter valued at about $39,000. Geode Capital Management LLC lifted its stake in OS Therapies by 31.1% during the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock valued at $344,000 after buying an additional 58,350 shares in the last quarter. Susquehanna International Group LLP purchased a new stake in OS Therapies during the third quarter valued at about $29,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in OS Therapies during the third quarter valued at about $40,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.